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Abstract. The clinical significance of determining sentinel lymph nodes (SLN) in patients with invasive cervical cancer 
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Oncology Department of the Cancer Research Institute. The day before surgery, four submucosal injections of 99mTc-
Al2O3 at a total dose of 80 MBq were made in each quadrant around the cervical tumor. Patients were submitted to 
preoperative lymphoscintigraphy and intraoperative SLN detection. The feasibility of preserving the reproductive 
potential in patients after radical abdominal trachelectomy was assessed. The 3-year, overall, disease-free and metastasis-
free survival rates were analyzed. Thirty-four SLNs were detected by single-photon emission computed tomography 
(SPECT) and 42 SLNs were identified by intraoperative gamma probe. The sensitivity in detecting SLNs was 100% for 
intraoperative SLN identification and 80% for SPECT image. The reproductive potential was preserved in 86% of 
patients. The 3-year overall and metastases-free survival rates were 100%. Recurrence occurred in 8.6% of cases.
Cervical cancer is the 5th most common cancer in women worldwide, reaching peak incidence in the 15 to 39 
age group [1, 2]. The treatment of early-stage cervical cancer can be life-saving for majority of patients, however, 
there is a high risk of irreversible infertility development [3, 4]. High survival rates in women of the reproductive 
age with early-stage cervical cancer encourage oncologists to improve the patients’ quality of life by performing an 
organ-preserving and functionally-sparing treatment [5–7]. Over the past years, abdominal radical trachelectomy has 
become more widely used for treating young women with FIGO stage IA2-IB2 invasive cervical cancer [1, 8, 9]. 
Radical abdominal trachelectomy (RAT) is a surgical procedure that removes the cervix, upper one-third of the 
vagina and lymph nodes in the pelvis, while preserving the ovaries, fallopian tubes and the uterine corpus that 
enables subsequent pregnancy and childbirth [2, 10–13]. Pelvic lymphodenectomy is performed fist and the 
removed lymph nodes are sent for routine pathological examination. If lymph nodes are positive, radical 
hysterectomy with ovarian transposition is performed. If cancer cells are not found in lymph nodes, the cervix with 
paracervical, parametrial tissues and upper one-third of the vagina are removed. A negative proximal resection 
margin should be histologically confirmed [1, 14, 15].
Thus, visualization and assessment of lymph nodes during surgical removal of the tumor in order to detect lymph 
node metastasis is of great importance. Micrometastases can only be diagnosed by microscopically, using 
morphological or molecular biology techniques [16–18].
Sentinel lymph node biopsy is becoming increasingly recognized as a standard technique for determining the 
status of lymphatic spread. The term “sentinel lymph node” was used for the first time by Gould in 1960 and 
supplemented then by R.M. Cabanas in 1977 [16, 19, 20]. The concept of sentinel lymph node is based on the theory 
of an orderly progression of tumor cells within the lymphatic system in the initial phase of the metastatic process, 
assuming that early lymphatic metastases are found first within the first-line tumor draining lymph node, the sentinel 
lymph node. If the SLN is free of metastatic disease, all other lymph nodes will also be free of disease [19, 21–23].
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Clinically, radioactive nanocolloids have been used for investigations of lymphatic drainage, and recently, more 
specifically for identification of the sentinel node in investigations of metastatic spread of some cancers [1, 2, 24]. A 
specific feature of 99mTc-Al2O3, a new radiopharmaceutical, is an organic coating of nanoparticles. During passage 
through the lymphatic system, nanoparticles lose their organic coating and accumulate in SLN without redistribution 
in the body. In addition, 99mTc-Al2O3 has an optimum nanoparticle size from 50 to 100 nm, whereby the tracer 
quickly leaves the injection site and migrates through the lymphatic system [6, 25, 26].
The purpose of the study was to evaluate the clinical significance of SLN detection in  patients with invasive 
cervical cancer using 99mTc-Al2O3, a new radiotracer based on technetium-99m-labeled gamma-alumina, to assess 
the reproductive potential of these patients and to analyze 3-year overall, disease-free and metastases-free survival 
rates [3, 4].
MATERIALS AND METHODS
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treated at the Gynecological Oncology Department of the Cancer Research Institute.
The day before surgery, four submucosal injections of 99mTc-Al2O3 at a total dose of 80 MBq (20 MBq per 
quadrant) were made around the cervical tumor. All patients were submitted to single photon emission computed 
tomography (SPECT) of the pelvis 18 hours after the injection of the radioactive isotope. Images were obtained 
using a double-headed gamma-camera (E.CAM 180, Siemens). A total of 16 projection images were recorded into a 
64u64 matrix (30 s per projection). The scan images were analyzed using the manufacturer software (e.soft, 
Siemens, Germany). Three-dimensional images of the abdomen, sagittal, transverse and coronal sections were 
obtained. 
For intraoperative detection of sentinel lymph nodes, the hand-held collimated Gamma Finder II® probe was 
used, which allowed the surgeon to precisely locate gamma radiation source and obtain accurate information about 
the distribution of the radionuclide in tissues and organs of the patient. The intraoperative detection of SLNs was 
performed by the surgeon after the opening of the retroperitoneal space. The registered gamma radiation level was 
displayed in numerical values (Fig. 1).
Then the patients underwent iliac-pelvic lymph node dissection. After lymph node dissection, the removed 
lymph nodes were re-examined with gamma probe to detect SLNs missed during intraoperative examination. The 
sentinel lymph node was marked and separately sent for express cytological examination (Fig. 2).
Patients, who had no metastases in SLNs, underwent radical abdominal trachelectomy. In cases with metastatic 
SLNs, extended hysterectomy with ovarian transposition was performed. Statistical analysis was performed using 
the IBM SPSS statistics 20.0 package.
(a) (b)
FIGURE 1. (a) Single photon emission computed tomography of the pelvis after injection of 99mTc-Al203;
(b) intraoperative SLN identification using Gamma Finder II®
Sentinel 
lymph nodes
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FIGURE 2. Re-examination of the removed lymph nodes using GammaFinder II®
The feasibility of preserving the reproductive potential was assessed in the group of patients who underwent 
organ-preserving treatment. To evaluate the reproductive potential preservation, the hormonal status of the ovaries 
was assessed by analyzing the levels of LH, FSH, estradiol, progesterone and testosterone. The maintenance of 
menstrual function after the treatment was also evaluated. The evaluation of the reproductive potential was carried 
out according to the formula: preservation of the reproductive potential (%) = all patients with the preserved 
hormonal and menstrual function/all patients in whom radical abdominal trachelectomy had been attempted ɏ 100%.
The 3-yaer overall, disease-free and metastases-free survival rates were assessed in all patients.
RESULTS AND DISCUSSION
The use of 99mTc-Al2O3 enabled SLNs to be identified by SPECT and intraoperative gamma probe procedure 
in all patients. A total of 34 SLNs were identified by SPECT. The intraoperative SLN assessment followed by the 
measurement of radioactivity in the removed lymph nodes allowed identification of 42 SLNs. The percentage of 
radiotracer uptake in SLNs was 7% by SPECT and 24% during surgery. The most common site for SLN detection 
was the external iliac region (57.2%), followed by the internal iliac (21.4%) and obturator (21.4%) regions. The 
comparison between the two techniques of SLN detection revealed that the intraoperative gamma probe detection 
technique was more effective than SPECT, demonstrating sensitivity of 100% compared to 80%. Imprint cytology 
and routine histological examination revealed metastases in regional lymph nodes in 6 patients and positive 
resection margins in 1 patient. Thus, 23 patients underwent radical abdominal trachelectomy (organ-preserving 
surgery) and 7 patients underwent extended hysterectomy with ovarian transposition. All patients with regional 
lymph node metastases and positive resection margins received 2 cycles of adjuvant chemotherapy.
To analyze the reproductive potential, the level of sex hormones and preservation of menstrual function were 
taken into account. Menstrual function was restored in all patients within three months after surgery. The normal 
level of sex hormones was observed in 20 (86.7%) patients. The reproductive potential was preserved in 86.7% of 
patients who underwent organ-preserving treatment. Pregnancy occurred in 3 patients.
None of the patients died within 3 years after treatment. In the first year of follow-up, 2 patients developed 
anastomotic recurrence. These patients received chemotherapy and had no evidence of recurrence during the next 
two years. There were no distant metastases.
The problems of the therapeutic role of SLN biopsy and clinical significance of metastases, which could not be 
identified by traditional imaging methods, are of great importance. The SLN biopsy allows small samples of lymph 
node tissue with a high prognostic value to be obtained.
The concept of SLN is especially valuable in cases where the status of lymph nodes is the most important factor 
for performing organ-preserving or adjuvant treatment, however the therapeutic role of complete lymphadenectomy 
is not clear.
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CONCLUSION
The novel radiotracer based on 99mTc-Al2O3 has high accumulation in sentinel lymph nodes without the 
evidence of further redistribution along the lymphatic collector, thus significantly facilitating scintigraphic and 
intraoperative SLN identification. The use of 99mTc-Al2O3 for detecting SLNs in patients with invasive cervical 
cancer demonstrated 100% sensitivity.
1. Based on the results of SLN biopsy, an individualized approach to surgical treatment of patients with invasive 
cervical cancer was used. Organ-preserving surgery was performed in 76% of patients and extended hysterectomy 
with ovarian transposition was performed in 24% of patients. The reproductive potential was preserved in 86.7% of 
patients.
2. The 3-year overall and metastases-free survival rates were 100%. Anastomotic recurrence was observed in 
2 patients (8.6%).
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